MENA 2024 Recordings-Diabetes Kidney Disease

Video Transcription

Video Summary

The presentation, given at an ACE event, focused on kidney health, particularly concerning diabetes-related chronic kidney disease (CKD). The speaker discussed recent advances in kidney therapy, emphasizing the importance of addressing the rising incidence of diabetes, especially in the MENA region, where cases are expected to surge significantly by 2045. Traditional treatments and recent positive trials in kidney health over the last five years were outlined, including FIGARO on Fidelio, Xanax CKD, and studies on SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin.<br /><br />The presentation stressed the significance of managing diabetes and CKD within the framework of lifestyle changes and the use of cutting-edge therapies such as RAS blockers, SGLT2 inhibitors, finerenone, and GLP-1 medications. The need for public policy improvements, capacity building, and increased awareness was highlighted to facilitate these treatments reaching more patients.<br /><br />Challenges in current practices were noted, such as under-prescription and testing inconsistencies, accompanied by high discontinuation rates of crucial medications. The call was made for better education, multidisciplinary approaches, and strategic efforts to integrate these treatments effectively into kidney disease management protocols.

Asset Subtitle

Dr. Sylvia Rosas

Keywords

chronic kidney disease

diabetes

SGLT2 inhibitors

kidney therapy

MENA region

public policy

treatment integration